Insights
What we publish, we have lived through on a mandate.
Current thinking on healthcare, life sciences, and capital in the GCC. No trend pieces, no reheated news, just the reads we would give a client working the same decision.
UAE healthcare regulatory & deal tracker Every instrument that changed how deals price, with the primary source for each.
Regulatory Brief9 July 2026Clinical AI in Abu Dhabi now needs a governance fileUnder the DOH Responsible AI Standard, every clinical AI tool a group deploys needs documented explainability, privacy controls, and accountability sign-off.Market Access8 July 2026UAE Family Office: DIFC vs ADGM, Decided FirstHow high-net-worth families should structure a UAE family office and holding vehicles across DIFC and ADGM, and why the framework has to be settled before assets are transferred.Deal Brief8 July 2026Diligence on a Hospital Group: What Moves PriceDiligence on a multi-site medical-center network or hospital group is a discipline in itself, and the findings that reprice a deal sit in payer concentration, denial rates, per-facility licence conditions, health-information connectivity, and the new UAE merger-control regime.
- 8 July 2026Regulatory BriefClinical costing: can your ERP reconcile to the EMR?Abu Dhabi's patient-level clinical costing requirement exposes the ERP-to-EMR integration gap most mid-size hospital groups still carry.
- 6 July 2026Strategy BriefAbu Dhabi's Advanced-Therapy Land GrabAbu Dhabi's wave of BIO 2026 advanced-therapy partnerships opens a positioning window for provider groups with research infrastructure to become trial sites and centres of excellence.
- 5 July 2026Infrastructure BriefAbu Dhabi's AED 55bn PPP Pipeline: Position NowAbu Dhabi's AED 55 billion PPP pipeline opens a health-infrastructure opportunity that rewards sponsors who arrive with grounded feasibility and a bankable financial model.
- 4 July 2026Board BriefWhy Geopolitical Risk Is Now a GCC Board Agenda ItemHow Red Sea logistics, war-risk exclusions, and force majeure disputes moved geo-risk onto the GCC board agenda.
- 4 July 2026Strategy BriefEntering UAE Healthcare: The Sequence That WorksWhy UAE healthcare entries fail on sequence rather than strategy, and the order that actually works.
- 4 July 2026Deal BriefUAE Healthcare M&A: What 2026 Buyers Pay ForThe gap between what sellers think drives a healthcare valuation and what 2026 buyers actually pay a premium for.
- 1 July 2026Market AccessGCC Expansion: One Market Is Not SixWhy GCC expansion demands country-by-country entry across six markets, disciplined distributor due diligence, and a Saudi strategy that does not assume the UAE approach carries over.
- 1 July 2026Deal BriefFinancing a Buy-and-Build Healthcare PlatformThe right mix of debt and equity for a scaling hospital or medical-center-group platform depends on its cash generation and its stage, and the GCC's 2026 capital markets now offer sukuk, private equity, and staged structures to match each one.
- 25 June 2026Workforce BriefThe 2027 Emiratisation Clock on Clinical RolesThe UAE's 2027 rule directing half of the 2% Emiratisation target to clinical roles turns Emiratisation into a workforce-planning problem your group should be solving through 2026.
- 23 June 2026Deal BriefWhat Earns a 10x Healthcare MultipleAmanat's completion of full ownership of Cambridge Health Group at an implied ~10.5x EBITDA on our own arithmetic shows that scale and margin quality, not top-line revenue, are what command the platform multiple.
- 19 June 2026Market AccessUAE Pharma Manufacturing: A Nine-Stage BuildThe nine-stage path from feasibility to WHO or EU GMP certification for UAE pharmaceutical manufacturing, and why localisation incentives do not shorten the qualification clock.
- 16 June 2026Strategy BriefThe Runway Before a DFM or ADX ListingWhy the premium multiple on a DFM or ADX listing is earned in the 18-to-24-month readiness window, and what an 18-point readiness assessment tests before the transaction begins.
- 13 June 2026Risk BriefForce Majeure Will Not Save an Unwritten ClauseWhy force majeure protection depends on clause scope and notification discipline, and how sanctions exposure can crystallise on contracts signed long before a designation.
- 12 June 2026Regulatory BriefDubai built a new licence line for longevity clinicsDubai's Law No. 17 of 2026 established the Dubai Longevity Authority to license the full longevity value chain, opening a planning window for anti-ageing, IV-wellness, regenerative and cell-therapy operators before the detailed rules land.
- 11 June 2026Operations BriefA High Denial Rate Costs You MoreDenial rates of 12-22% against a managed benchmark below 5% are a bigger prize than pricing, and Avior runs revenue cycle as a discipline rather than a reaction.
- 9 June 2026Regulatory BriefEDE Drug Registration: There Is No Verification RouteHow UAE marketing authorisation actually works under the Emirates Drug Establishment: one standard eCTD route scaled by product class, a separate 90-working-day pricing clock, and no reliance pathway for products approved by the FDA or EMA.
- 5 June 2026Operations BriefWhere the Missing Margin Points WentThe gap between a 4% margin and a 12-18% benchmark is built and lost in service-line economics, pricing and procurement, and Avior recovers it with tracked impact.
- 28 May 2026Market AccessDHA and DOH Licensing: Sequence Before LeaseWhy UAE healthcare facility licensing under DHA or DOH must run in strict sequence, and how a stage-two decision determines what happens at stage six.
- 22 May 2026Regulatory BriefThree Emirates, Three Compliance Regimes, One CalendarA multi-site group across Dubai, Abu Dhabi and Sharjah now carries three renewal calendars, three connectivity mandates and three penalty schedules, and needs one unified compliance spine to govern them.
- 21 May 2026Regulatory BriefSharjah tightened its health rulebook: map your sitesSharjah's 2026 amendment adds administrative penalties across government, private and free-zone facilities and their professionals, so groups with Sharjah sites need a Sharjah-specific policy map and a per-clinician re-credentialing plan.
- 16 May 2026Deal BriefWhy Healthcare and Pharma M&A Is DifferentWhat separates a healthcare or pharma acquisition from generic M&A, and why the valuation runs longer.
- 12 May 2026Market AccessUAE Business Setup: Free Zone, Mainland or DIFCWhy the free zone, mainland and DIFC or ADGM decision must be modelled against Corporate Tax and banking at establishment, not treated as paperwork.
- 9 May 2026Deal BriefArada's Reem Deal Opens a New Exit RouteA property developer's AED 2 billion commitment to Reem Hospital signals that strategics chasing recurring revenue now sit alongside PE and sovereigns as credible buyers for scalable multi-site healthcare brands.
- 22 April 2026Regulatory BriefUAE Merger Control Hits Healthcare DealsThe UAE's new merger-control regime forces pre-closing clearance on many healthcare deals, so regulatory runway and UBO disclosure now belong in the deal timeline.
- 26 February 2026Regulatory BriefThe End of UAE Pharma ExclusivityThe end of the exclusive-distributor model in the UAE is an M&A and re-contracting catalyst that favours distributors with cold-chain, hospital and tender infrastructure.
- 18 November 2025Regulatory BriefDubai's claims rulebook now puts your permit at riskDubai's PD-05-2025 rebuilds the claim lifecycle around eClaimLink with hard SLAs and permit-level penalties, forcing hospital and medical-center groups to run revenue cycle natively rather than around the system.
- 3 November 2025Regulatory BriefDay-case DRG in Abu Dhabi: coding now sets marginAbu Dhabi's move to case-based DRG for day-case procedures shifts margin from fee-for-service billing to coding accuracy and resource control.